STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sutro Biopharma Inc (STRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, a bullish technical setup, and a promising pipeline with mid-2026 catalysts. Despite weak financials, the company's innovative platform and potential for best-in-class efficacy make it a compelling long-term investment.
The technical indicators are bullish. The MACD is positive and expanding (0.325), indicating upward momentum. The RSI is neutral at 75.153, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its first resistance level (R1: 29.584), suggesting potential for further upside.
Bullish technical indicators and a solid cash position of $212M.
Weak financial performance in Q4 2025, with revenue down -21.35% YoY, net income down -35.45% YoY, and EPS down -39.07% YoY. Lack of recent news or significant hedge fund/insider trading activity.
In Q4 2025, revenue dropped to $11.65M (-21.35% YoY), net income fell to -$46.76M (-35.45% YoY), and EPS decreased to -5.35 (-39.07% YoY). However, gross margin remained strong at 100%.
Analysts are overwhelmingly positive on STRO. Recent upgrades include Deutsche Bank raising the price target to $55, Citizens to $35, and Wells Fargo to $27. Analysts highlight the company's innovative ADC platform, solid cash position, and potential for STRO-004 to deliver best-in-class efficacy and safety.
